Dr. Vladimir Mulens-Arias is currently a research associate at the Dr. Domingo F Barber´s Lab at the Immunology and Oncology Department, National Center for Biotechnology of Madrid, Spain (CNB-CSIC), under a Juan de La Cierva-Incorporation contract. During the 14-years-span scientific experience, Dr. Mulens-Arias has contributed with high-impact research to cancer immunotherapy and nanomedicine fields. Currently, he is involved in the elucidation of the effect of metallic nanoparticles on immunoproteasome function, and thus, antigen presentation machinery in human tumor cells, and how it can modulate the formation of neo-antigens that activate the immune system. Before his current appointment, Dr. Vladimir Mulens-Arias worked as a research associate at the Center for Molecular Immunology (CIM)-a pharmaceutical company- within the first 4 years after university (4 papers published on clinical trial results). He developed his Ph.D. program (CNB- La Caixa International Ph.D. Program) upon successfully being granted an international & competitive Ph.D. fellowship in cancer nanotechnology at National Center for Biotechnology, under supervision of Dr. Domingo F Barber Castaño (8 publications published, including top journals in biomaterials, nanomedicine, & nanotechnology field such as Biomaterials and Journal of Controlled Release). He was a pioneer in demonstrating the intrinsic biological activities of magnetic nanoparticles, specifically those coated with polyethyleneimine, opening the new application in cancer therapy. Granted one of the competitive international postdoctoral scholarship grants from ARC Fondation, he worked on the application of biogenic extracellular vesicles in cancer theranostic as well as in the development of plasmonic nanoparticle-based nanoplatforms for cancer imaging and therapy, at Dr. Florence Gazeau (Laboratoire Matière et Systèmes Compléxes, Paris Diderot University), a pioneer in using extracellular vesicles as therapeutic agents (5 publications published, including top journals such as Nanoscale & Advanced Drug Delivery Review). He developed a new gold nanocluster-based therapeutic agent for colorectal carcinoma, proved the convenience of conjugate 5-fluorouracil with gold nanoparticle for colorectal carcinoma treatment, and elucidated the immunological effect of cell-derived extracellular vesicles loaded with magnetic nanoparticles for the future development of immunotherapies.